{"id":1810,"date":"2023-03-16T14:53:00","date_gmt":"2023-03-16T13:53:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1810"},"modified":"2024-03-30T14:56:33","modified_gmt":"2024-03-30T13:56:33","slug":"18c-liecivo-abemaciklib-liek-verzenios-v-kombinacii-s-fulvestrantom-v-1-a-2-linii-liecby-u-pacientov-s-lokalne-pokrocilym-alebo-metastatickym-hr-her2-karcinomom-prsnika-so-skorym-nastupom-relap","status":"publish","type":"post","link":"https:\/\/niho.sk\/en\/18c-liecivo-abemaciklib-liek-verzenios-v-kombinacii-s-fulvestrantom-v-1-a-2-linii-liecby-u-pacientov-s-lokalne-pokrocilym-alebo-metastatickym-hr-her2-karcinomom-prsnika-so-skorym-nastupom-relap\/","title":{"rendered":"18C: Lie\u010divo abemaciklib (liek Verzenios) v kombin\u00e1cii s fulvestrantom v 1. a 2. l\u00ednii lie\u010dby u pacientov s lok\u00e1lne pokro\u010dil\u00fdm alebo metastatick\u00fdm HR+\/HER2- karcin\u00f3mom prsn\u00edka so skor\u00fdm n\u00e1stupom relapsu alebo progresie ochorenia s predch\u00e1dzaj\u00facou endokrinnou terapiou"},"content":{"rendered":"<ol class=\"wp-block-list\">\n<li><strong>Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Karcin\u00f3m prsn\u00edka je celosvetovo naj\u010dastej\u0161\u00edm n\u00e1dorov\u00fdm ochoren\u00edm u \u017eien a aj naj\u010dastej\u0161ou pr\u00ed\u010dinou \u00famrtia \u017eien v s\u00favislosti s onkologick\u00fdm ochoren\u00edm. Metastatick\u00fd karcin\u00f3m prsn\u00edka sa pova\u017euje za nevylie\u010dite\u013en\u00fd, pacientky s\u00fa lie\u010den\u00e9 nekurat\u00edvnou lie\u010dbou. N\u00e1stup ochorenia je sp\u00e1jan\u00fd s v\u00fdrazne zhor\u0161enou kvalitou \u017eivota a vytv\u00e1ra psychick\u00fa z\u00e1\u0165a\u017e nielen na pacientky, ale aj bl\u00edzkych, ktor\u00ed sa sna\u017eia ich podporova\u0165 a pom\u00e1ha\u0165 im.<\/p>\n\n\n\n<p>Karcin\u00f3m prsn\u00edka u \u017eien je naj\u010dastej\u0161ou pr\u00ed\u010dinou \u00famrt\u00ed spojen\u00fdch s rakovinou a vyskytuje sa naj\u010dastej\u0161ie u postmenopauz\u00e1lnych \u017eien vo veku po 50 roku \u017eivota. Karcin\u00f3m prsn\u00edka sa vyskytuje aj u mu\u017eov hoci ve\u013emi zriedkavo, tvor\u00ed pribli\u017ene 1 % v\u0161etk\u00fdch pr\u00edpadov karcin\u00f3mu prsn\u00edka.<\/p>\n\n\n\n<ol class=\"wp-block-list\" start=\"2\">\n<li><strong>O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Verzenios je protirakovinov\u00fd liek obsahuj\u00faci \u00fa\u010dinn\u00fa l\u00e1tku abemaciklib.&nbsp;<\/p>\n\n\n\n<p>Abemaciklib blokuje \u00fa\u010dinky bielkov\u00edn naz\u00fdvan\u00fdch cykl\u00edndependentn\u00e1 kin\u00e1za 4 a 6. Tieto bielkoviny s\u00fa abnorm\u00e1lne akt\u00edvne v niektor\u00fdch rakovinov\u00fdch bunk\u00e1ch a sp\u00f4sobuj\u00fa ich nekontrolovan\u00fd rast.&nbsp;<\/p>\n\n\n\n<p>Blokovanie \u00fa\u010dinku t\u00fdchto bielkov\u00edn m\u00f4\u017ee spoma\u013eova\u0165 rast rakovinov\u00fdch buniek, vies\u0165 ku zmen\u0161eniu n\u00e1doru a oddialeniu postupu ochorenia.<\/p>\n\n\n\n<p>Verzenios bol registrovan\u00fd Eur\u00f3pskou liekovou agent\u00farou pre hodnoten\u00fa indik\u00e1ciu d\u0148a 26.09.2018.&nbsp;<\/p>\n\n\n\n<ol class=\"wp-block-list\" start=\"3\">\n<li><strong>Ako sa na abemaciklib pozeraj\u00fa odborn\u00edci?&nbsp;<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Klinick\u00fd odborn\u00edk, pacientska organiz\u00e1cia OZ Amazonky a Slovensk\u00e1 onkologick\u00e1 spolo\u010dnos\u0165 by priv\u00edtali kategoriz\u00e1ciu v\u0161etk\u00fdch takzvan\u00fdch CDK4\/6 inhib\u00edtorov, \u010d\u00edm by sa zmen\u0161ila frustr\u00e1cia s administrat\u00edvou vybavovania v\u00fdnimiek na lie\u010divo, ktor\u00e9 sa v zahrani\u010d\u00ed pou\u017e\u00edva ako \u0161tandard lie\u010dby a bolo by pr\u00edstupnej\u0161ie v\u00e4\u010d\u0161iemu po\u010dtu pacientov.<\/p>\n\n\n\n<ol class=\"wp-block-list\" start=\"4\">\n<li><strong>\u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Dr\u017eite\u013e registr\u00e1cie (Eli Lilly Nederland B.V. (NLD)) podal \u017eiados\u0165 o zaradenie lieku Verzenios (lie\u010divo abemaciklib) do \u00fahrad z verejn\u00e9ho zdravotn\u00e9ho poistenia pri pou\u017eit\u00ed v kombin\u00e1cii s fulvestrantom v 1. a 2. l\u00ednii lie\u010dby u pacientov s lok\u00e1lne pokro\u010dil\u00fdm alebo metastatick\u00fdm HR+\/HER2- karcin\u00f3mom prsn\u00edka so skor\u00fdm n\u00e1stupom relapsu alebo progresie ochorenia s predch\u00e1dzaj\u00facou endokrinnou terapiou<\/p>\n\n\n\n<p class=\"has-custom-highlight-background-color has-background\">\u017diados\u0165 sp\u013a\u0148a z\u00e1konn\u00e9 krit\u00e9ri\u00e1, pokia\u013e:&nbsp;<\/p>\n\n\n\n<ul class=\"has-custom-highlight-background-color has-background wp-block-list\">\n<li>\u017eiadate\u013e poskytne z\u013eavu, aby cena sp\u013a\u0148ala krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti a<\/li>\n\n\n\n<li>sa uprav\u00ed indika\u010dn\u00e9 obmedzenie \u200b\u200btak, \u017ee lie\u010dba bude hraden\u00e1 iba pacientk\u00e1m s lok\u00e1lne pokro\u010dil\u00fdm neoperovate\u013en\u00fdm karcin\u00f3mom.<\/li>\n<\/ul>\n\n\n\n<p>NIHO z\u00e1rove\u0148 odpor\u00fa\u010da:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>po\u017eadova\u0165 dodato\u010dn\u00fa z\u013eavu, vzh\u013eadom na vysok\u00fa neistotu hodnovernosti modelovania d\u00e1t a<\/li>\n\n\n\n<li>zv\u00e1\u017ei\u0165 doplnenie indika\u010dn\u00e9ho obmedzenia o to, aby\n<ul class=\"wp-block-list\">\n<li>hradeniu predch\u00e1dzal s\u00fahlas zdravotnej pois\u0165ovne&nbsp;<\/li>\n\n\n\n<li>aby mal pacient dobr\u00fd v\u00fdkonnostn\u00fd stav<\/li>\n\n\n\n<li>aby nebola hraden\u00e1 pacientom s lok\u00e1lne pokro\u010dil\u00fdm karcin\u00f3mom.<\/li>\n<\/ul>\n<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u017diados\u0165 sp\u013a\u0148a z\u00e1konn\u00e9 krit\u00e9ri\u00e1, pokia\u013e&#8230;<\/p>","protected":false},"author":3,"featured_media":1806,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[70,71],"class_list":["post-1810","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-abemaciklib","tag-verzenios"],"_links":{"self":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1810"}],"version-history":[{"count":0,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1810\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media\/1806"}],"wp:attachment":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}